TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.

Stanley B Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.